Shaan GandhiDirector at Northpond Ventures
Shaan C. Gandhi is a Director at Northpond Ventures and leads the firm’s work in biotechnologies. Shaan is a board director at Aro Biotherapeutics; CAMP4 Therapeutics; Candel Therapeutics; DiCE Molecules; StrideBio, Inc.; Triumvira Immunologics, Inc.; and Vigil Neuroscience. Previously, Shaan was a Principal at the Longwood Fund, where he created and invested in life sciences companies, including Pyxis Oncology, a cancer immunotherapy company focused on novel modulators of the tumor microenvironment, which he co-founded and served as President. Prior to Longwood, he was an attending hospitalist at Massachusetts General Hospital, where he also did his residency in internal medicine. He holds an MD from Harvard Medical School; an MBA from Harvard Business School, where he was a Baker Scholar; a D.Phil. in medical oncology from the University of Oxford, where he was a Rhodes Scholar; and a B.S. with honors in biochemistry from Case Western Reserve University. Shaan is the Secretary/Treasurer of the Suffolk District Medical Society, the professional medical society of Boston, and a Trustee of the Boston Medical Library.